The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Manoj Kumar Reddy
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.0 pts more than Nifty Microcap 250 and 5.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Promoters of Concord Drugs Limited — S. Nagi Reddy, S. Koni Reddy and S Manoj Kumar Reddy — subscribed to a preferential allotment on November 20, 2025. Together the promoter group acquired 5 lakh equity shares (about 3.8% of expanded equity) and 18 lakh convertible warrants (about 13.7% on a diluted basis). The company's equity share capital rose from 1 crore to 1.3175 crore shares. After the allotment, the promoter group's total holding crossed to roughly 58.74% of the expanded equity base, up from 54.39% earlier. The acquisition was made under Reg 29(2) of the SEBI Takeover Regulations and the company filed the disclosure with BSE on November 22, 2025.
This is a promoter stake increase funded by their own capital, signalling insider confidence in the company. However, retail shareholders face dilution since the preferential issue expanded the share base by about 31%.